Iron isomaltoside for the treatment of iron deficiency anemia：a rapid health technology assessment
- VernacularTitle:异麦芽糖酐铁治疗缺铁性贫血的快速卫生技术评估
- Author:
Xuting LIU
1
;
Shengnan GAO
2
;
Ran QI
1
;
Guiping DU
1
;
Guoqiang LIU
1
Author Information
1. Dept. of Pharmacy，the Third Hospital of Hebei Medical University，Shijiazhuang 050051，China
2. Hebei Institute for Comprehensive Evaluation of Medicine and Health Technology，Shijiazhuang 050051，China
- Publication Type:Journal Article
- Keywords:
iron isomaltoside;
iron deficiency anemia;
rapid health technology assessment
- From:
China Pharmacy
2022;33(24):3040-3044
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the effectiveness， safety and economy of iron isomaltoside in the treatment of iron deficiency anemia using a rapid health technology assessment （HTA） method， and provide an evidence-based basis for clinical decision-making. METHODS PubMed， Embase， Cochrane Library， CNKI， Wanfang database and foreign HTA official websites were systematically searched， and the search time frame of the databases was from the establishment of the database to May 25th 2022. After data extraction and quality evaluation of the literature according to the inclusion and exclusion criteria， a descriptive analysis of the effectiveness， safety and economy of iron isomaltoside in the treatment of iron deficiency anemia was performed. RESULTS & CONCLUSIONS A total of 1 HTA report， 3 systematic reviews/meta-analysis and 5 economic studies were included. In terms of effectiveness， compared with ferric carboxymaltose， the hemoglobin level of patients using iron isomaltoside increased more， but there was no significant difference in the proportion of responding patients； compared with iron sucrose， it had non- inferiority in increasing and maintaining hemoglobin level， and there was no difference in the quality of life. In terms of safety， the incidence of adverse events of ferric carboxymaltose， iron sucrose and iron isomaltoside were 12.0%， 15.3% and 17.0%， respectively. Iron isomaltoside had a lower incidence of hypophosphatemia， compared with ferric carboxymaltose. There was no statistical difference in the incidence of hypophosphatemia among iron isomaltoside， iron sucrose， iron-dextrin and nanocrystalline iron oxide. The conclusion of the incidence of treatment-emergent adverse event， the incidence of serious adverse events and the withdrawal rate of patients due to adverse events was not clear. In terms of economy， the economy of iron isomaltoside is better than that of iron sucrose， and the economy of iron isomaltoside versus that of ferric carboxymaltose had not been finalized.
